XOMA WILL GET ROYALTY FROM NEW GENENTECH EYE DRUG

Xoma Ltd. said it will be paid a royalty on sales of Lucentis, a Genentech Inc. drug recently approved to treat a leading cause of blindness. Lucentis, approved by the Food and Drug Administration to treat wet age-related macular degeneration, an eye disorder, was developed by Genentech using Xoma's bacterial cell expression technology.
Bizjournals